Actionable news
0
All posts from Actionable news
Actionable news in KTOV: KITOV PHARAMCEUTICALS HOLDINGS Ltd. AMERICAN DEPOSITARY SHARES,

Kitov Creates Pill For Safely Treating Osteoarthritis Pain And Hypertension

By combining two existing generic drugs, a new, safer solution to osteoarthritis pain is found.

Kitov’s drug passed Phase III with stunning results.

FDA application will follow, and marketing to this multi-billion dollar market could commence in 2017.

Risks include possible lower efficacy and greater side effects when used in a large population.

Stock owners could benefit from a quicker than usual return on investment.

Drug companies run the range of novel new therapies and creative use of older medicines. This latter category is exciting because FDA approval is easier - clinical trials have already been done and safety issues solved. But not all pharma firms travel this path successfully until Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV), whose work treating a pervasive worldwide medical condition costing healthcare billions of dollars, found a way.

Kitov takes existing drugs and makes them work better together. Its first indication is osteoarthritis (NYSE:OA), or degenerative joint disease where cartilage of the hips, knees and spine breaks down and inflammation sets in, causing pain. The condition gradually worsens, and no cure exists. Over-the-counter pain relievers are the drug of choice, but they cause an increase in blood pressure which, in turn, can lead to cardiovascular disease (NYSE:CVD).

Ingeniously mixing celecoxib, a non-steroidal anti-inflammatory drug (NSAID) originally marketed by Pfizer Inc. (NYSE:PFE) as Celebrex until going generic in 2014, and amlodipine besylate, another Pfizer drug sold as Norvasc for lowering blood pressure until patent expiration in 2007, Kitov's lead compound, KIT-302, tackles pain and the unfortunate result of using NSAIDs for pain - hypertension. Nothing like it has been developed before.

Late last year, Kitov scored big when its drug hit a primary efficacy endpoint in Phase III in a trial designed to measure drops in blood pressure in those receiving KIT-302. Separated into four groups, 152 patients treated over two weeks received KIT-302, Norvasc alone, Celebrex alone, or placebo. Trial results were analyzed after 17 months, post-treatment, its goal to show Kitov's drug lowered daytime...


More